about
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancerVeliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoproteinFlavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaA dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary CancerClinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemiaPhase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk diseaseEnterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
P50
Q28306292-4D106D43-D769-4FB7-B527-02252C787B6BQ33429801-EAB599FF-80B8-45F4-A8D9-9DBFB6035C56Q33440533-444AB5D0-0309-4712-8096-DAD48B395FDBQ33627721-04F390DE-4B01-46B1-9E76-AB2AA11DDBB4Q33952759-1DFD6601-7F30-4A00-8076-3CAA6EC28863Q35187824-262D8B7F-0079-494B-89D8-D5DA9C2A6B43Q35615823-E1B4ACF9-7BA2-4910-A301-28B81B74421DQ36520182-EF7CECCC-9DF8-44E5-9C86-F7EFD39BA373Q36972551-2B583DE2-787A-4CE0-860A-56EBB8CA7BC7Q37142145-0C6EEFC6-EBC4-44FB-8327-BCD15B3A3482Q37339628-D3FC9176-AC59-4F04-963A-3746A851D482Q37398150-A83221E4-5318-4AD3-9580-1B0E171F5BB5Q37474415-F9AD67A7-1B70-4DAB-93AE-3862E6196009Q37558026-5EDC1C61-3EE0-4FBA-85B2-7FF9E1850D5FQ37587057-0A6564F6-F37A-424D-9AC5-E101080A315C
P50
description
onderzoeker
@nl
name
Larry J Schaaf
@ast
Larry J Schaaf
@en
Larry J Schaaf
@nl
Larry J Schaaf
@sl
type
label
Larry J Schaaf
@ast
Larry J Schaaf
@en
Larry J Schaaf
@nl
Larry J Schaaf
@sl
prefLabel
Larry J Schaaf
@ast
Larry J Schaaf
@en
Larry J Schaaf
@nl
Larry J Schaaf
@sl